Cellebrite DI (CLBT) Common Equity (2020 - 2025)

Cellebrite DI (CLBT) has reported Common Equity for 6 consecutive years, with $484.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity rose 44.13% year-over-year to $484.3 million; the TTM figure through Dec 2025 stood at $484.3 million (up 44.13% YoY), while the FY2025 annual figure was $484.3 million, up 44.13% from the prior year.
• Common Equity came in at $484.3 million for Q4 2025 at Cellebrite DI, up from $336.0 million in the prior quarter.
• The five-year high for Common Equity was $484.3 million in Q4 2025, with the low at -$73.3 million in Q4 2021.
• Average Common Equity over 5 years is $171.0 million, with a median of $73.9 million recorded in 2022.
• Across the five-year window, Common Equity slumped 214.96% in 2021 and surged 882.17% in 2024, its largest moves.
• Year by year, Common Equity stood at -$73.3 million in 2021, then jumped by 200.71% to $73.9 million in 2022, then slumped by 53.68% to $34.2 million in 2023, then soared by 882.17% to $336.0 million in 2024, then soared by 44.13% to $484.3 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $484.3 million, $336.0 million, and $34.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.